Description
OVERVIEWProduct overview
This vial contains modified GRF (1-29) and ipamorelin blended together, the pairing most often used when both arms of the growth hormone axis are studied at once.
Literature on the combination examines whether GHRH and ghrelin receptor stimulation together produce a different release profile than either alone.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
SUPPLY IN IRELANDCJC-1295 (no DAC) & Ipamorelin Ireland — supplied to research laboratories
Research groups across Ireland buy CJC-1295 (no DAC) & Ipamorelin from Kensington Laboratories as a lyophilised CJC-1295 (no DAC) & Ipamorelin peptide, released only against a batch-matched certificate of analysis. Every vial of high purity CJC-1295 (no DAC) & Ipamorelin is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering CJC-1295 (no DAC) & Ipamorelin in Ireland receive material with documented purity and identity.
Laboratory CJC-1295 (no DAC) & Ipamorelin is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning CJC1295(noDAC)&Ipamorelin research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for CJC-1295 (no DAC) & Ipamorelin peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
CJC-1295 (no DAC) & Ipamorelin is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 10 mg per vial
- Peptide class: Pre-blended GHRH analogue and ghrelin receptor agonist
- Also known as: Mod GRF (1-29) and ipamorelin blend
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
This vial contains modified GRF (1-29) and ipamorelin blended together, the pairing most often used when both arms of the growth hormone axis are studied at once.
Literature on the combination examines whether GHRH and ghrelin receptor stimulation together produce a different release profile than either alone.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- Combined GHRH and GHS-R signalling
- Pulsatile release profiles in animal models
- Selectivity and off-target endocrine measures
- Comparative single-compound arms
Scientific context and proposed mechanisms
The GHRH analogue acts at the GHRH receptor while ipamorelin acts at the ghrelin receptor; authors describe the two pathways as complementary.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-CJC1295NOD-2409A
- Testing laboratory
- Janoshik Analytical, s.r.o.
- Date tested
- 12 August 2026
- Reported purity
- 99.79%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
The independent result for this batch is summarised above. Contact the laboratory team if you need the full report for this batch.
